Clinical trials: Overactive Bladder, completed
Detrusor Overacitivity
Comparisons of Phasic and Terminal DO
Overactive bladder is a common issue among women of childbearing age, regardless of their childbirth experience. Some of these women may exhibit detrusor overactivity in urodynamic studies.
- Trial name
- NCT06793046
- Where
- Taiwan
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Overactive Bladder
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
This study will evaluate the efficacy and safety of DA-8010 in patients with overactive bladder for 12 weeks as double-blind, placebo-controlled and active-reference study, and also will evaluate the long-term safety of DA-8010…
- Trial name
- NCT05282069
- Testing
- DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg
- Where
- South Korea
- Volunteers
- 607 people
- Sponsor
- Dong-A ST Co., Ltd.
Urinary Bladder, Overactive
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
Prospective, double-blind, double-dummy, 2-arm, parallel-group, design. Flexible dose regimen for solifenacin succinate, fixed dose treatment regimen for tolterodine. Assessment of OAB symptoms by patient diaries.
- Trial name
- STAR (NCT00802373)
- Testing
- Solifenacin succinate, Tolterodine
- Where
- 95 sites in Belarus, Belgium and 15 more
- Volunteers
- 1,355 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder (OAB)
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.
- Trial name
- NCT03903094
- Testing
- Non-Interventional
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 6,295,279 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Overactive Detrusor
Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
The purpose of this study is to find out whether plantarflexion has an effect on the degree of urinary urgency and on the amplitude of detrusor contraction during filling cystometry in patients with detrusor overactivity (DO).
- Trial name
- DO (NCT01837654)
- Testing
- Plantarflexion 2nd wave, Plantarflexion - 3rd wave
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Assaf-Harofeh Medical Center
Overactive Bladder
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
To evaluate the safety and efficacy of SSR240600C versus placebo on clinical and cystometric parameters in patients with OAB and UUI.
- Trial name
- NCT00174798
- Testing
- SSR240600C, Tolterodine
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- Sanofi
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Toviaz Post Marketing Surveillance Study
The objective of this study is to determine the problems and questions of safety and efficacy of Toviaz® under the standard conditions of usage.
- Trial name
- NCT00879398
- Testing
- Toviaz treatment
- Where
- 82 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Effect of Ureteral Stents Length and Location on Related Symptom
This is a prospective randomized clinical trial, evaluating the effect of the intra-ureteral placement of the stent's distal end versus the conventional stent placement on the postoperative LUTS and pain.
- Trial name
- NCT05069376
- Testing
- Ureteral Stent of 5-16 or 5-18, Ureteral Stent of 5-22 or 5-24
- Where
- Taiwan
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Overactive Bladder Syndrome
Cyclic Versus Continuous Sacral Neuromodulation for LUTS
This will be a prospective, randomized-controlled multi-site trial comparing cyclic versus continuous sacral neuromodulation (SNM) for OAB.
- Trial name
- NCT06170450
- Testing
- Cyclic SNM, Continuous SNM
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Overactive Bladder Syndrome, Coronary Artery Disease
Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease
Investigators aimed to investigate the association between over active bladder and coronary artery disease as demonstrated on coronary angiography.
- Trial name
- NCT02854813
- Where
- Turkey (Türkiye)
- Volunteers
- 250 people
- Sponsor
- Ankara Training and Research Hospital
Urinary Incontinence, Urinary Bladder, Overactive
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
This study will evaluate real world pattern of use of BOTOX® in actual clinical practice in patients with idiopathic overactive bladder (iOAB) with urinary incontinence whose symptoms have not been adequately managed by oral…
- Trial name
- GRACE (NCT02161159)
- Testing
- botulinum toxin Type A
- Where
- 54 sites in Germany, Spain and 2 more
- Volunteers
- 515 people
- Sponsor
- Allergan
Overactive Bladder Syndrome
Prevalence And Risk Factors of Overactive Bladder Syndrome Among Egyptian Medical Students, and Their Impact On Health-Related Quality Of Life
Overactive bladder (OAB) is defined as sudden, urgent desire to urinate (urgency) accompanied by frequency and nocturia, with or without urgent urinary incontinence in the absence of urinary tract infection (UTI).
- Trial name
- NCT07044778
- Testing
- Questionnaire
- Where
- Egypt
- Volunteers
- 1,003 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Overactive Bladder
Post Marketing Surveillance Study on Emselex After Launch in Germany
Data are obtained of Emselex in routine treatment of Overactive Bladder. The general objectives are to evaluate the product safety, compatibility, efficacy and patient acceptance.
- Trial name
- NCT00786448
- Testing
- Darifenacin, Emselex (BAY79-4998)
- Where
- Germany
- Volunteers
- 5,821 people
- Sponsor
- Bayer
Overactive Bladder, Urinary Frequency or Urgency Adverse Event
Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up
Long term open label study on safety and durability of the Urgent-SQ tibial implant device for refractory overactive bladder syndrome (OAB).
- Conditions
- Overactive Bladder, Urinary Frequency or Urgency Adverse Event, Urinary Incontinence, Urge
- Trial name
- NCT01644409
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Radboud University Medical Center
Benign Prostatic Hyperplasia (BPH), Overactive Bladder
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.
- Trial name
- NCT04485585
- Testing
- BR9006-1, BR9006-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Overactive Bladder
A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks
The purpose of this study is to evaluate the rate of "add-on" solifenacin treatment and its persistency in men with over active bladder symptoms after tamsulosin monotherapy for 4 weeks.
- Trial name
- NCT00884104
- Testing
- Solifenacin
- Where
- 9 sites in South Korea
- Volunteers
- 307 people
- Sponsor
- KYU-SUNG LEE